HALO FY 2022 Earnings Report — Halozyme Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

Halozyme Therapeutics, Inc.HALO

FY 2022 Earnings

Reported February 21, 2023

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2022	Prior Q	FY 2021	QoQ Change	YoY Change
Revenue	$660M	—	$443M	—	48.9%
Op. Income	$268M	—	$276M	—	-3.0%
Gross Margin	78.9%	—	81.6%	—	-2.7pp
Net Margin	30.6%	—	90.8%	—	-60.2pp
EPS (Diluted)	$1.44	—	$2.74	—	-47.4%
Free Cash Flow	$235M	—	$298M	—	-21.0%

Revenue Flow

Item	Amount
REVENUE	$660M
Cost of Revenue	$139M
GROSS PROFIT	$521M
R&D Expenses	$67M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$144M
Other Expenses	$43M
Operating Expenses	$253M
Cost & Expenses	$393M
OPERATING INCOME	$268M
Interest Income	$0
Interest Expense	$17M
Other Income/Expenses	-$19M
INCOME BEFORE TAX	$249M
Income Tax Expense	$47M
Net Income from Continuing Ops	$202M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$202M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$202M
D&A	$50M
EBIT	$266M
EBITDA	$316M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$660M
Cost of Revenue	$139M
GROSS PROFIT	$521M
R&D Expenses	$67M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$144M
Other Expenses	$43M
Operating Expenses	$253M
Cost & Expenses	$393M
OPERATING INCOME	$268M
Interest Income	$0
Interest Expense	$17M
Other Income/Expenses	-$19M
INCOME BEFORE TAX	$249M
Income Tax Expense	$47M
Net Income from Continuing Ops	$202M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$202M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$202M
D&A	$50M
EBIT	$266M
EBITDA	$316M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$202M
Depreciation & Amortization	$57M
Stock-Based Compensation	$24M
Deferred Income Tax	$0
Other Non-Cash Items	$67M
Change in Working Capital	-$110M
OPERATING CASH FLOW	$240M
Capital Expenditure	-$5M
Acquisitions (Net)	-$999M
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	$517M
NET CASH FROM INVESTING	-$487M
Net Debt Issuance	$625M
Common Stock Repurchased	-$200M
Common Dividends Paid	$0
Other Financing Activities	-$62M
NET CASH FROM FINANCING	$362M
FREE CASH FLOW	$235M
Net Change in Cash	$115M

Balance Sheet

Item	Amount
Cash & Equivalents	$234M
Short-Term Investments	$129M
Net Receivables	$231M
Inventory	$100M
Other Current Assets	$45M
TOTAL CURRENT ASSETS	$739M
PP&E (Net)	$76M
Goodwill	$409M
Intangible Assets	$547M
Long-Term Investments	$0
Tax Assets	$44M
Other Non-Current Assets	$27M
TOTAL NON-CURRENT ASSETS	$1.1B
TOTAL ASSETS	$1.8B
Account Payables	$18M
Short-Term Debt	$13M
Deferred Revenue	$3M
Other Current Liabilities	-$3M
TOTAL CURRENT LIABILITIES	$131M
Long-Term Debt	$1.5B
Deferred Revenue NC	$2M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$46M
TOTAL NON-CURRENT LIABILITIES	$1.5B
TOTAL LIABILITIES	$1.7B
Common Stock	$135.0K
Additional Paid-In Capital	$27M
Retained Earnings	$143M
Treasury Stock	$0
Accum. Other Comp. Income	-$922.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$170M
Minority Interest	$0
TOTAL EQUITY	$170M
TOTAL LIABILITIES & EQUITY	$1.8B
Total Debt	$1.5B
Net Debt	$1.3B